KRAS and lung carcinoma: In this work, we found LTB4R2 to be a druggable essentiality gene in SCC, whereas in a previous work we found LTB4R2 to be a vulnerability specifically associated with the presence of KRAS mutation in lung AD [9]; thus, the sensitivity to the KO of this gene may be context-specific and not limited to a single lung cancer subtype.